|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Dedicated CRA ¸ðÁý -ÆĶô¼¿ÄÚ¸®¾Æ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.11 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ -CRA & Dedicated CRA
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.08 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ- CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.04 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Dedicated CRA / CRA
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
07.25 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ- °æ·Â CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ)º§¸óÆ®¸®½áÄ¡ |
(ÁÖ)º§¸óÆ®¸®½áÄ¡ ½ÅÀÔ / °æ·Â CRA ¸ðÁý
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.24 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ Á¤±ÔÁ÷ CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.08 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Clinical Lead (for Dedicated CRA) ¸ðÁý -ÆĶô¼¿ÄÚ¸®¾Æ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
07.16 |
|
|
PRA Health Sciences |
CRA, Sr. CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.18 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.28 |
|
|
´õ¿þÀÌÄ¿¹Â´ÏÄÉÀÌ¼Ç |
ÀÓ»ó½ÃÇè CRA °æ·ÂÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
02.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.02 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.01 |
|
|
(ÁÖ)¹ÙÀÌ¿À¸®´õ½º |
¹ÙÀÌ¿À¸®´õ½º ºñÀÓ»óÆÀ °æ·ÂÁ÷ ä¿ë
°æ±â ¿ëÀνà | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
05.04 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.19 |
|